Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes

Established in 1927 by the American College of Physicians

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes

View this table:

[in a new window]

Table 1. Patient Characteristics, Diagnoses, and Treatment

View this table:

[in a new window]

Table 2. Outcome after Treatment with Antithymocyte Globulin

View this table:

[in a new window]

Table 3. Univariate and Multivariate Logistic Regression Analyses for Predicting Response

View larger version (25K):

[in a new window]

Figure 1. Overall survival of the 61 patients enrolled in the study.Top. Five-year probability of survival was 76% (95% CI, 64% to 88%). Dotted lines represent the upper and lower boundaries of confidence intervals. Bottom. Covariate-adjusted survival for responders and nonresponders. Response status was ascertained at 8 months after treatment with antithymocyte globulin.

View this table:

[in a new window]

Table 4. Univariate and Multivariate Cox Regression Analyses for Mortality

View larger version (26K):

[in a new window]

Figure 2. Overall time to progression (to refractory anemia with excess blast cells in transformation or to acute myelogenous leukemia) for the 61 patients enrolled in the study.Top. Five-year probability of remaining progression free was 90% (95% CI, 80% to 100%). Dotted lines represent the upper and lower boundaries of confidence intervals. Bottom. Covariate-adjusted time to progression for responders and nonresponders. Response status was ascertained at 8 months after treatment with antithymocyte globulin.

View this table:

[in a new window]

Table 5. Univariate and Multivariate Cox Regression Analyses for Leukemic Progression